Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial

Salvatore Minisola*, Fernando Marin, David L. Kendler, Piet Geusens, Cristiano A. F. Zerbini, Luis A. Russo, Enrique Casado, Astrid Fahrleitner-Pammer, Jan J. Stepan, Eric Lespessailles, Ruediger Moericke, Alicia Bagur, Peter Lakatos, Pedro Lopez-Romero, Jean Jacques Body

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Web of Science)
Original languageEnglish
Article number10
Number of pages8
JournalArchives of Osteoporosis
Volume14
Issue number1
DOIs
Publication statusPublished - 18 Jan 2019

Keywords

  • Teriparatide
  • Fractures
  • Postmenopausal osteoporosis
  • 25-Hydroxy-vitamin D
  • Subgroup analysis
  • Bisphosphonates
  • BONE-MINERAL DENSITY
  • VITAMIN-D DEFICIENCY
  • POSTMENOPAUSAL WOMEN
  • 25-HYDROXYVITAMIN-D
  • OSTEOPOROSIS
  • ASSOCIATION
  • HIP

Cite this